Salus Science Corporation

Greetings

What can we do for facing Pancreatic cancer?

In November 2022, we founded “Salus Science Corp.” with the aim of translating the results derived from our basic research on pancreatic cancer into practical application in the clinical field. Pancreatic cancer is one of the most malignant cancers, and even in medically advanced countries, its 5-year survival rate is less than 10%. The development of biomarkers and new treatment methods for pancreatic cancer is strongly desired by the world to save the lives of many pancreatic cancer patients.

We will start with the “human pancreatic cancer organoid transplant mouse” business and the “pancreatic cancer research antibody” business. Our future business development will consist of two pillars: development of diagnostic agents and development of therapeutic agents. For diagnostic agents, we are moving forward with the practical application of diagnostic markers that are useful for early diagnosis and biomarkers that can predict the effects of chemotherapy. For therapeutic agents, we are working to establish new chemotherapy combination therapies and develop therapeutic agents such as nucleic acid drugs. We are developing these scientific technologies together with our partners to put them into practical use, and our goal is to bring about a future in which the survival rate of pancreatic cancer becomes better and better, which is the summit we are aiming for.

We will do our utmost to save the lives of as many pancreatic cancer patients as possible. We would like to ask for your continued support.

Miki Taniuchi
Representative Director and CEO

Research results must be utilized in clinical practice,
can contribute to society.

Representative Director, Keisuke Taniuchi

Associate Professor and Chair of Gastroenterology, Kochi University School of Medicine
Doctor of Medicine, Gastroenterologist
Kochi Medical University Graduate School of Medicine (known as Kochi University School of Medicine)

Studied basic pancreatic cancer research at the Human Genome Center, Institute of Medical Science, University of Tokyo, and the Eppley Cancer Institute, University of Nebraska Medical Center. Based on the results of his consistent basic and clinical research, he is engaged in the development of diagnostic markers and drug targets. In November 2022, he participated in the establishment of the Company as a scientific founder. His mission is to commercialize biomarkers and drugs directly linked to the improvement of pancreatic cancer prognosis in the clinical field.

MyPortal researchmap

Our Philosophy

We respect the dignity of life and aim to contribute to the development of pancreatic cancer research.

Aiming to improve the prognosis of pancreatic cancer, we will earnestly tackle the challenges of practical application of new scientific technologies and contribute to the development of early diagnosis and new treatment methods for pancreatic cancer.